iBio (NYSEMKT:IBIO) Shares Down 3.6%

iBio, Inc. (NYSEMKT:IBIO)’s stock price traded down 3.6% during trading on Wednesday . The company traded as low as $1.81 and last traded at $1.88. 269,653 shares changed hands during mid-day trading, an increase of 138% from the average session volume of 113,212 shares. The stock had previously closed at $1.95.

iBio Stock Down 3.6 %

The business has a fifty day moving average of $1.63. The company has a quick ratio of 0.91, a current ratio of 0.91 and a debt-to-equity ratio of 0.04.

Hedge Funds Weigh In On iBio

Several institutional investors have recently bought and sold shares of the stock. HighTower Advisors LLC bought a new position in shares of iBio in the first quarter valued at approximately $25,000. State Street Corp grew its stake in iBio by 55.7% in the 1st quarter. State Street Corp now owns 48,059 shares of the company’s stock valued at $100,000 after buying an additional 17,200 shares during the last quarter. US Bancorp DE raised its holdings in iBio by 178.4% in the 1st quarter. US Bancorp DE now owns 67,100 shares of the company’s stock worth $29,000 after acquiring an additional 43,000 shares during the period. Charles Schwab Investment Management Inc. lifted its position in iBio by 10.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 586,227 shares of the company’s stock worth $252,000 after acquiring an additional 54,084 shares during the last quarter. Finally, Dimensional Fund Advisors LP bought a new stake in iBio during the fourth quarter valued at about $33,000. 7.90% of the stock is currently owned by institutional investors.

About iBio

iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.